INOVIQ Ltd (ASX:IIQ) Advances EXO-OC™ Commercialisation Pathway Following Independent Technical Review

Sonal Goyal

30 September 2026 02:23 PM AEST

INOVIQ Ltd (ASX:IIQ) Advances EXO-OC™ Commercialisation Pathway Following Independent Technical Review

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

INOVIQ Ltd (ASX:IIQ) completed an independent technical review of its EXO-OC™ diagnostic program following outcomes from the OC2200 verification study.
The review identified pre-analytical sample collection and handling differences as the largest source of study variability.
The company confirmed a staged optimisation, clinical verification and laboratory validation pathway to progress EXO-OC™ towards a US Laboratory Developed Test (LDT).
INOVIQ is targeting completion of laboratory validation activities by H1 CY2028, subject to successful completion of development stages.

INOVIQ Ltd (ASX:IIQ) is a biotechnology company developing exosome-based diagnostics and therapeutics, including its EXO-OC™ blood test for ovarian cancer detection. The company’s shares were trading at AUD 0.18, up nearly 9% on 30 September 2026 at 12:06 pm. INOVIQ has announced findings from an independent technical review of its OC2200 study and outlined a revised development pathway to advance EXO-OC™ towards potential US Laboratory Developed Test (LDT) commercialisation.

Independent Review of OC2200 Study Findings

INOVIQ commissioned an independent review following the completion issues associated with the OC2200 verification study. The review was conducted by Dr Mathew Moore PhD, Principal of US-based contract diagnostics organisation ResearchDx.

The objective of the review was to assess the company’s internal analysis, identify factors contributing to variability in the study outcome and provide recommendations for future development of EXO-OC™.

The independent assessment confirmed that INOVIQ’s Technical Analysis of the OC2200 study was accurate and reproducible. The review identified differences in pre-analytical sample collection, processing and handling across five commercial biorepositories as the largest contributor to variability in biomarker measurements.

EXO-OC™ Program Findings and Optimisation Focus

The OC2200 study involved evaluation of EXO-OC™, an exosome-based blood test being developed for early detection of ovarian cancer. According to INOVIQ, the study samples contained lower measurable miRNA biomarker levels compared with the earlier OC500 study.

The reduced availability of quantifiable biomarker data limited assessment of the EXO-OC™ multi-marker algorithm across the full OC2200 cohort.

Despite these limitations, the independent review identified evidence supporting the biological relevance of EXO-OC™. Samples collected from a single collection site demonstrated differentiation between ovarian cancer and benign gynaecological conditions.

The review recommended focusing future development activities on tumour-specific extracellular vesicle capture optimisation, refinement of the biomarker panel and implementation of consistent sample collection protocols before additional clinical evaluation.

Staged Development Pathway Towards US LDT

INOVIQ has established a staged optimisation and validation program to progress EXO-OC™ towards US LDT readiness.

The first stage, assay optimisation, commenced in Q3 CY2026 and focuses on enhancing EXO-NET® technology for tumour-specific extracellular vesicle capture and refining the EXO-OC™ biomarker panel.

The second stage involves clinical verification using an independent cohort of average and high-risk women with ovarian cancer collected under standardised protocols.

The third stage involves laboratory validation, including technology transfer, optimisation and validation with a US CAP/CLIA-certified laboratory partner. INOVIQ is targeting completion of this stage in H1 CY2028.

Following successful laboratory validation, EXO-OC™ could progress towards deployment as a US Laboratory Developed Test, with commercial launch, pricing and reimbursement activities expected to be led by the laboratory partner.

Biospecimen Strategy and Commercial Development

INOVIQ is evaluating selected biobanks, academic institutions and specialist clinical sites across Australia and the United States to support verification, validation, regulatory and reimbursement activities.

The company plans to undertake sample Acquisition and laboratory validation activities in collaboration with specialist partners to support the development pathway.

INOVIQ stated that its existing EXO-OC™ research workflows are compatible with clinical laboratory integration and support automated, high-throughput processing.

EXO-OC™ Technology and Market Opportunity

EXO-OC™ is an exosome-based blood test designed for early detection of ovarian cancer in asymptomatic women. The technology uses INOVIQ’s EXO-NET® platform to isolate exosomes and combines multiple exosomal miRNA biomarkers with CA125 in an artificial intelligence and Machine Learning algorithm.

The company previously reported early detection performance from a 498-sample retrospective case-control study, including reported sensitivity results across early-stage and all-stage ovarian cancer samples at a specified specificity level.

INOVIQ is initially pursuing a US LDT pathway for women at elevated risk of ovarian cancer, with a longer-term objective of developing EXO-OC™ as an in-vitro diagnostic for broader screening applications.

Risks and Uncertainty

Biotechnology development programs involve risks associated with clinical validation, regulatory requirements, laboratory processes, funding requirements and commercial adoption. EXO-OC™ remains under development and requires further optimisation, verification and validation before potential commercial deployment.

Key Takeaways

INOVIQ’s independent review of the OC2200 study has provided additional information on the factors affecting study variability and guided a revised development pathway for EXO-OC™. The company is now progressing a staged optimisation and validation program focused on improving assay performance, standardising sample collection and advancing towards a potential US LDT pathway. Future clinical and laboratory validation activities will determine the progress of the diagnostic program.

FAQs

Q: What is EXO-OC™?

A: EXO-OC™ is INOVIQ’s exosome-based blood test under development for early detection of ovarian cancer.

Q: What caused variability in the OC2200 study?

A: The independent review identified differences in pre-analytical sample collection, processing and handling across biorepositories as the largest source of variability.

Q: What did the independent review confirm about EXO-OC™?

A: The review confirmed that INOVIQ’s technical assessment was accurate and identified evidence supporting the biological relevance of the technology.

Q: What are the next stages for EXO-OC™ development?

A: The company plans to undertake assay optimisation, clinical verification and laboratory validation before potential LDT commercialisation.

Q: When is INOVIQ targeting laboratory validation completion?

A: INOVIQ is targeting completion of laboratory validation activities by H1 CY2028, subject to successful completion of development stages.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.